新薬開発の現状

INTRODUCTION/SUMMARY

Drug discovery technology involves innumerable assays to determine the molecular affinities and potential toxic effects of drug candidates. In the past decade, through the application of combinatorial chemistry and genomics, the number of drug candidates has increases logarithmically. To sort through these now astronomical numbers of potential blockbusters, the pharmaceutical industry has applied increasingly miniaturized and robotic assays systems.

Miniaturization not only saves on scarce resources, such as purified proteins, but also decreases the time, another precious commodity, involved in doing assays.

Nanotechnology involves the miniaturization of devices beyond microengineering; however, at nanoscale, materials can have quite different properties, as different physical principles, for instance, van der Wall's forces, become more dominant. Intuitive understanding of forces like friction or surface tension are not useful at the nano level. Nanostructured materials may be very much stronger and lighter than conventional bulk materials. Some nanostructured materials have new and unexpected properties, such as "quantum dots" that fluoresce at different wavelengths depending upon their size. Nanomaterials may be used to create nanodevices with defined functions.

Biomolecules such as protein and DNA are also easily exploited to make nanodevices. Like fullerenes, biomolecules generally have a carbon backbone, but one that is widely substituted with modifiable chemical groups. Because their biochemistry is well understood, DNA and proteins are being used structurally now to build nanodevices.

The favorite manufactured items used by nanotechnologists have diameters comparable to smallest objects found in nature. Six-carbon atoms lined end to end are about 1 nm in diameter. Perhaps surprisingly, the synthetic molecule, buckminster fullerene, which contains 60 carbons, has the same diameter. Despite the large molecular weight, because C60 is approximately spherical is minimal. Even so, C60 can be made to cage other molecules, including some used for medical imaging purposes. Fullerene derivatives, such as nanotubes, have smaller diameters than C60. Commercially available nanoparticles are actually quite a bit smaller than cells, about the same size as an average virus.

It is apparent that nanoscale fabrication has already reached the scale of biomolecules. The problem that remains is how to apply nanotechnology to biomedical requirements, and even more difficult, how to make it marketable. Nanoscale devices are now being used for contrast agents for imaging purposes, for bioassays, as drug delivery agents, and even as drug equivalents.

The topics found in the following archive include:

• Basic Science
• Biomimetics
• Designer Macromolecules
• Diagnostics and Analytics
• Drugs and Drug Delivery
• Molecular Motors
• Nanotools
• Nanotubes and Nanowires
• Fluidics
• Imaging
• Informatics
• Thin Films
• Industry News
• Patents

• BCC ON-LINE SERVICES
  • INTERNET

• THE SYNTHETIC GENOME PROJECT
• POWER SUPPLY FOR ARTIFICIAL CELLS
  • POWER SUPPLY FOR ARTIFICIAL CELLS (CONTINUED)

• GROWTH HORMONE KEEPS OLD RATS FIT
• TOO MANY BACTERIA CAUSE ULCERS
  • TOO MANY BACTERIA CAUSE ULCERS (CONTINUED)
• HIV-LIKE VIRUS IN WILD CHIMPS
• TURNING OFF INFLAMMATION
• POLYOMA VIRUS LINKED TO BRAIN TUMORS
  • POLYOMA VIRUS LINKED TO BRAIN TUMORS (CONTINUED)
• MOUSE MODEL FOR MYELOID LEUKEMIA
• SUPER-STAPH INVADES HOSPITALS WORLDWIDE
• ENTER THE VISIBLE MOUSE
  • ENTER THE VISIBLE MOUSE (CONTINUED)
• SUPRESSING GENES IN C. ELEGANS
• CELL MIGRATION KEY TO SCHIZOPHRENIA
• HELPING FRUIT FLIES TO REMEMBER
• NEW THEORY OF DRUG ACTION
• SPIN RESONANCE REVEALS STRUCTURE
• LIPID ACTIVATES CLOT FORMATION
• RAT MODEL OF EPILEPSY CREATED
• THERMOGENESIS MAY BE KEY TO OBESITY
• MOTOR PROTEIN AMPLIFIES SOUND
• GECKOS EMPLOY VAN DER WAALS FORCE
  • GECKOS EMPLOY VAN DER WAALS FORCE (CONTINUED)
• PLASMON WAVEGUIDES FOR STUDYING MEMBRANES
• PLASMON RESONANCE MEASURES BINDING
• 'SMART DUST' SENSES BIOMOLECULES
  • 'SMART DUST' SENSES BIOMOLECULES (CONTINUED)
  • 'Smart Dust' Senses Biomolecules (Continued)

• GRID-COMPUTING ENABLES RESEARCH
• DIAGNOSTIC TOOLS TO BE DEVELOPED
• MALARIA PARASITE, MOSQUITO SEQUENCED
  • MALARIA PARASITE, MOSQUITO SEQUENCED (CONTINUED)
  • Malaria Parasite, Mosquito Sequenced (Continued)
  • Malaria Parasite, Mosquito Sequenced (Continued)
• AWARD FOR CHEMICAL INTELLIGENCE PLATFORM
• GRANT AWARDED FOR "COMPUTATIONAL BIOLINGUISTICS"
  • GRANT AWARDED FOR "COMPUTATIONAL BIOLINGUISTICS" (CONTINUED)
• NANOBARCODES USED TO SCORE SNPs
• WEBSITE OFFERS SNP INFO

• NATURE TO SHOW NASA THE WAY
• TINY ORGANIC MUSCLES, TENDONS AND PUMPS
• CORRALLING THE WILD MAGNETIC VORTEX
  • CORRALLING THE WILD MAGNETIC VORTEX (CONTINUED)
• SILVER BINDING PEPTIDES GENERATE CRYSTALS

• TRANS-PACIFIC ARTHRITIS DEAL
• PROFILING DEAL FOR HIV INFECTION
• ADA, ENTELOS SET DIABETES FORUM
• INHALE TO PEGYLATE THROMBOPOIETIN
• JOINT EFFORT TO FIND GCPR LIGANDS
• MUSCULAR DYSTROPHY COLLABORATIVE DEAL
• SINGLE CHAIN ANTIBODY AGREEMENT
• AGREEMENT COVERS PROTEOSOME INHIBITORS
• DRUG SALVAGE OPERATION BEGUN
• TRANS-PACIFIC PROTEOMICS PACT
• DRUG DISCOVERY CONTRACT SIGNED
• AVIVA AND AXON ANNOUNCE AGREEMENT
• DARK SIDE OF THE GENOME EXPLORED
• DECLARING WAR ON ANTIBIOTIC RESISTANCE
• MS CLINICAL RESEARCH AGREEMENT
• COLLABORATION ADDS INVERSE GENOMICS
• NEOGENESIS LAUNCHES TWO COLLABORATIONS
  • NEOGENESIS LAUNCHES TWO COLLABORATIONS (CONTINUED)

• FERRITIN USED TO CREATE STORAGE MEDIA

• NANOTECH, BIOTECH CONVERGE IN CT
  • NANOTECH, BIOTECH CONVERGE IN CT (CONTINUED)
  • NANOTECH, BIOTECH CONVERGE IN CT (CONTINUED)
  • NANOTECH, BIOTECH CONVERGE IN CT (CONTINUED)
  • NANOTECH, BIOTECH CONVERGE IN CT (CONTINUED)

• RNA INTERFERENCE COLLABORATION INITIATED
• DESIGNER POLYMERS THAT SELF-ASSEMBLE
  • DESIGNER POLYMERS THAT SELF-ASSEMBLE (CONTINUED)
• AMBION WINS SIRNA GRANT
• MANUFACTURING MESH WITH MICROBIAL MOLECULES
  • MANUFACTURING MESH WITH MICROBIAL MOLECULES (CONTINUED)

• U.S. MARKET FOR BIOSENSORS AND BIOELECTRONICS TO CROSS $1.81 BILLION BY 2006
• Table 1 U.S. MARKET FOR BIOSNESORS AND BIOELECTRONICS, THROUGH 2006 ($ MILLIONS)
• Figure 1 U.S. MARKET FOR BIOSNESORS AND BIOELECTRONICS, 2001 AND 2006 ($ MILLIONS)
  • US. MARKET FOR MEDICAL IMAGING AND RELATED PRODUCTS TO REACH NEARLY $10 BILLION BY 2007
• Table 2 U.S. USER EXPENDITURES FOE MEDICAL IMAGING EQUIPMENT AND RELATED PRODUCTS, THROUGH 2007 ($ MILLIONS)
• Figure 2 U.S. USER EXPENDITURES FOE MEDICAL IMAGING EQUIPMENT AND RELATED PRODUCTS, 2000-2007 ($ MILLIONS)
  • GLUTAMINE SYNTHETASE MARKS ALZHEIMER'S
  • STOOL TEST FOR COLON CANCER
    • STOOL TEST FOR COLON CANCER (CONTINUED)
  • DETECTING INFECTION BY SUBTRACTION
  • PATTERNS REVEAL OVARIAN CANCER
  • BLOOD TEST FOR CONGESTIVE HEARTS
  • SYNTHETIC ANTIBODIES USED AS SENSORS
  • BRANCHED-CHAIN HEP C TEST
  • RIGHTS TO OVARIAN TUMOR MARKERS
  • PROTEIN ASSOCIATED WITH CANCER
  • NANOPARTICLES USED TO FINGERPRINT PATHOGENS
    • NANOPARTICLES USED TO FINGERPRINT PATHOGENS (CONTINUED)
  • DNA SEPARATION BY SIEVE
  • DETECTION DEVICE FOR BIOWARFARE AGENTS
  • TATTOO TO MONITOR BLOOD GLUCOSE LEVELS
  • PCR IN SUB-NANOLITER VOLUMES
  • CONNECTING TITANIUM DIOXIDE TO DNA
  • MICROFLUIDIC DEVICE TO DETECT MULTIPLE VIRUSES
  • VERTICAL CAVITY SURFACE EMITTING LASER BUILT
  • QUANTUM DOTS MAKE FROGS FLUORESCENT
  • GRANT FOR MICROFLUIDIC DEVICES
    • GRANT FOR MICROFLUIDIC DEVICES (CONTINUED)

• NANOPARTICLE DELIVERS TO THE EYE
• HYDROFLUOROALKANE FOR DELIVERING DRUGS
• IMPLANT DELIVERS DRUGS TO EYE
• GO AHEAD-INHALE, IT'S LEGAL
• TESTS SPEED HIV, HCV DIAGNOSIS
• DEPOMED SUES BRISTOL-MYERS SQUIBB
• MAKING MICROSPHERES FOR DRUG DELIVERY
• IMPLANT BLOCKS VASOSPASM
• PROTEIN AND PEPTIDE DELIVERY SYSTEM
• INHALEABLE PEPTIDE SUBJECT OF COLLABORATION
• EAT YOUR CORN, IT'S GOOD FOR YOU
• ENCAPSULATION PROCESS PATENTED
• LIGHT PULLS LIQUID THROUGH TUBES
• CHIPS FOR DRUG DELIVERY
• QUANTUM DOTS HOME ON CANCER
• TREATING CANCER WITH MRI PROCEDURE
• MOLECULAR TRANSPORTERS OPEN CELL'S GATES
• PATENT FOR BIOSILICON ISSUED
• PARTICLES ACT AS ADJUVANT
• NUCLEIC ACID-TRIGGERED DRUG RELEASE
• ISOLATED ORGANELLE AS A VACCINE
• ANTIBODIES ADDED TO NANOPARTICLE CARRIERS
  • ANTIBODIES ADDED TO NANOPARTICLE CARRIERS (CONTINUED)

• NANOVOLUME CRYSTALLIZATION YIELDS STRUCTURES

• INHIBITOR AND BLOCKER MARKET TO CROSS $176 BILLION BY 2006
• Table 3 WORLDWIDE MARKET FOR INHIBITORS AND BLOCKERS, THROUGH 2006 ($ MILLIONS)
• Figure 3 WORLDWIDE MARKET FOR INHIBITORS AND BLOCKERS, 2001 AND 2006 ($ MILLIONS)
  • TUMORS DEPEND ON POLYAMINE
  • TRP TRNA SYNTHETASE IS ANTI-ANGIOGENIC
  • ANGIOGENESIS INHIBITOR BINDS TO INTEGRIN
    • ANGIOGENESIS INHIBITOR BINDS TO INTEGRIN (CONTINUED)
  • TARGETS FOR CANCER THERAPY PATENTED
  • PROTEIN ESSENTIAL FOR HIV ASSEMBLY
  • WATER TRANSPORT IN THE LUNG
  • ENZYME PROMOTES MULTIPLE SCLEROSIS
  • TNF-ALPHA AFFECTS CELL DEATH
    • TNF-ALPHA AFFECTS CELL DEATH (CONTINUED)
  • LEPTIN PROMOTES BLOOD CLOTS
  • GENE LINKED TO VENTRICLE FORMATION
  • ENZYME REPAIRS OXIDATIVE DAMAGE
    • ENZYME REPAIRS OXIDATIVE DAMAGE (CONTINUED)
  • POLYMERASE ERRORS CAUSE MUSCLE DISEASE
  • MANGANESE BLOCKS HIV REPLICATION
  • ACID-ACTIVATED PROTEIN PLAYS ROLE IN LEARNING
    • ACID-ACTIVATED PROTEIN PLAYS ROLE IN LEARNING (CONTINUED)
  • COMPLEX DRIVES PLATELET SHAPE
  • SUPPRESSOR MISSING IN PROSTATE CANCER
  • QUORUM SENSING STRUCTURE SOLVED
  • FINDING SIGNALS FOR OBESITY
  • DRUG RESISTANCE PATENT ISSUED
  • HUNTINGTON'S DISRUPTS BRAIN MITOCHONDRIA
    • HUNTINGTON'S DISRUPTS BRAIN MITOCHONDRIA (CONTINUED)

• MEDICAL SENSORS FROM NANOANTENNAS
• ZOOMING OUT WITH LEAP
• POTATO HEAD PARTICLE LIGHTS UP PLAQUES
• COATING MAKES MRI IMPLANTS SAFE
• YES, VIRGINIA, THERE IS A SANTA CLAUS
• VIEWING ATOMIC MAGNET FIELDS

• CANTILEVER BATTERY TO POWER IMPLANTS
• NITINOL DEVICE DOES HEAVY LIFTING
  • NITINOL DEVICE DOES HEAVY LIFTING (CONTINUED)

• MARKET FOR DRUGS AND COSMETICS CONTINUE TO TAP THE AGING BABY BOOMERS GENERATION
• Table 4 VALUE OF THE AGING BABY BOOMER PHARMACEUTICAL & COSMETIC SALES ¾ U.S., THROUGH 2006 ($ MILLIONS AT MANUFACTURERS' LEVEL)
• Figure 4 VALUE OF THE AGING BABY BOOMER PHARMACEUTICAL & COSMETIC SALES ¾ U.S., 2001 AND 2006 ($ MILLIONS AT MANUFACTURERS' LEVEL)
  • MARKET FOR REPRODUCTIVE TECHNOLOGIES CONTINUES TO EVOLVE IN THE COMING YEARS
• Table 5 MARKET FOR REPRODUCTIVE TECHNOLOGY PRODUCTS AND PROCEDURES, THROUGH 2006 ($ MILLIONS)
• Figure 5 MARKET FOR REPRODUCTIVE TECHNOLOGY PRODUCTS AND PROCEDURES, 2001 AND 2006 ($ MILLIONS)
  • WORLDWIDE DIABETES MARKET TO CROSS $26.8 BILLION BY 2007
• Table 6 WORLDWIDE DIABETES MARKET, THROUGH 2007 ($ MILLIONS)
• Figure 6 WORLDWIDE DIABETES MARKET, 2000-2007 ($ MILLIONS)
  • U.S. MARKET FOR MEDICAL DIAGNOSTIC KITS TO CROSS $5 BILLION BY 2006
• Table 7 U.S. MDK APPLICATIONS MARKET AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2006 ($ MILLIONS)
• Figure 7 U.S. MDK APPLICATIONS MARKET AT U.S. MANUFACTURERS' SALES LEVELS, 2001 AND 2006 ($ MILLIONS)
  • GLOBAL MARKET FOR PHARMACEUTICAL (DRUG) INERT INGREDIENTS TO REACH NEARLY 4.2 BILLION KGS BY 2006
    • GLOBAL MARKET … BY 2006 (CONTINUED)
• Table 8 GLOBAL MARKET FOR PHARMACEUTICAL (DRUG) INERT INGREDIENTS, THROUGH 2006 (MILLIONS OF KG)
  • U.S. GENERIC PRESCRIPTION DRUG INDUSTRY TO CROSS $19 BILLION BY 2006
• Table 9 THE U.S. GENERIC DRUG MARKET, THROUGH 2006 ($ BILLIONS)
• Figure 8 PERCENTAGE OF THE U.S. GENERIC DRUG MARKET HELD BY LEADING THERAPEUTIC CATEGORIES, 2001
  • THE $400 BILLION WORLDWIDE DRUG INDUSTRY CONTINUES TO EVOLVE
    • REPORT FINDINGS
• Table 10 TRENDS IN DRUG SALES, THROUGH 2007 ($ BILLIONS)
  • CONTRACT FOR BIOTERROR CONTROL
  • BURRILL OPENS SHOP ON BIOSTREET
  • CARDIOME ACQUIRES PARALEX, HEART DRUG
  • FIRST LICENSING OF APTAMERS
  • BUSH BUDGETS FOR BIOTERROR MEASURES
    • BUSH BUDGETS FOR BIOTERROR MEASURES (CONTINUED)
  • PRIVATE ACCREDITATION FOR HUMAN CLINICALS
  • AUSTRALIAN BIOTECH GETS A NEWS OUTLET
  • HOMELAND HEALTH OFFERS BIOPREPAREDNESS
  • BATTLE IN SEATTLE OVER ENBREL
  • WHAT MAKES ALCOHOLICS DRINK?
  • IVAX BUYS MERCK'S GENERICS BUSINESS
  • NO ECONOMIES OF SCALE
  • YAMANOUCHI COMES TO AMERICA
  • AUSTRALIAN STEM CELLS AVAILABLE
  • APOPTOSIS GOES COMMERCIAL
  • AGING INSTITUTE FUNDS COMPANY
  • SULFATION PATHWAYS FOCUS OF NEW FIRM
  • MORE AUTONOMY FOR PHARMA UNITS
  • DESPITE OBSTACLES, BIOTECH MARCHES ON
    • DESPITE OBSTACLES, BIOTECH MARCHES ON (CONTINUED)
  • BRISTOL-MYERS SUED AGAIN
  • BIOVAIL LICENSES METFORMIN PRODUCT
  • GENENTECH TO PAY $300 MILLION
  • MERCK TO REFILE ARCOXIA NDA
  • PHRMA SUES FEDERAL GOVERNMENT
  • U.S. AIDS FOUNDATION TAKES ON GLAXO
  • QUARK ACQUIRES INCYTE'S MICROARRAY ASSETS
  • REALITY DEPRESSES AIDS RESEARCHERS
  • MEDICINES FOR AGING AMERICANS
  • DOES THE INDUSTRY NEED ANOTHER MERGER?
    • DOES THE INDUSTRY NEED ANOTHER MERGER? (CONTINUED)
  • ENGINEERING AND LIFE SCIENCES CONVERGING
  • ROCHE LICENSES ALZHEIMER'S COMPOUNDS
  • CHINA ESTABLISHES NANOTECHNOLOGY CENTER
  • BIOTECH FIRM SPUN OUT OF COVENTOR
  • GRANT TO BUILD NANOTECH CENTER
  • IS U.S. BEING OUTSPENT TWO TO ONE ON NANO?
  • NANOGEN, COMBIMATRIX SETTLE SUIT
  • ZYVEX, HONEYWELL TEAM UP
  • SANDIA TO FOCUS ON LIFE SCIENCES
    • SANDIA TO FOCUS ON LIFE SCIENCES (CONTINUED)
  • NANO READY TO MOVE, SAYS U.K. SURVEY
  • PENN STATE GETS NEW NANOSCIENCE CENTER
  • SMALL TECH HITS THE BIG TIME
  • SHOULD THE GENIE BE KEPT BOTTLED?
  • NANOSPHERE BAGS VC FUNDS
  • CARBON NANOTECH GROUP FORMED IN TAIWAN
  • TRITON BIOSYSTEMS SWALLOWS THERMONIX
  • BRIEFLY NOTED
    • CEPHEID AND APPLIED BIOSYSTEMS GROUP TO DEVELOP AND MARKET REAGENTS
    • GENEMACHINES LAUNCH OMNIGRID 300 MICROARRAYER
    • CAPSULUTION NANOSCIENCE AND DEUTSCHE GELATINE-FABRIKEN STOESS AG, EBERBACH SIGNED AGREEMENT.
    • METRICS GROUP PUBLISH TECHNICAL INTELLIGENCE PROFILE REPORT
    • STARPHARMA GET U.S. PATENT OK
    • BIOFORCE NANOSCIENCES RECEIVE TOTAL EQUITY INVESTMENT
    • OXFORD BIOSENSORS TO PROGRESS FROM PRODUCT DEVELOPMENT INTO PRODUCT MANUFACTURE

• DISCOVERY, TECHNOLOGY AND DRUGS TO COME
  • DISCOVERY, TECHNOLOGY AND DRUGS TO COME (CONTINUED)
  • DISCOVERY, TECHNOLOGY AND DRUGS TO COME (CONTINUED)
  • DISCOVERY, TECHNOLOGY AND DRUGS TO COME (CONTINUED)
  • DISCOVERY, TECHNOLOGY AND DRUGS TO COME (CONTINUED)

• DRAFT MOUSE SEQUENCE AVAILABLE
• FROM CHEMICAL TO CLINICAL
• HUNTINGTON'S DISEASE GENE DATABASE
• LINKING IMAGES TO EXPERIMENTAL DATA
  • LINKING IMAGES TO EXPERIMENTAL DATA (CONTINUED)
• PENNSYLVANIA CREATES BIOINFORMATICS CONSORTIUM
• VISUALIZATION OF DRUG INTERACTIONS
• SUPERCOMPUTER CRUNCHES AWAY FOR TULARIK
• HUMAN HAPLOTYPE MAP TO BE CREATED
• OF MICE, MEN AND THEIR GENES
  • OF MICE, MEN AND THEIR GENES (CONTINUED)
  • Of Mice, Men and their Genes (Continued)

• RESTORING SIGHT WITH RETINAL IMPLANTS
• TRANSATLANTIC MEMS CO-OPERATION
  • TRANSATLANTIC MEMS CO-OPERATION (CONTINUED)

• IMAGINING AND MODELING THE INVISIBLE
• SOFTWARE FOR MODELING MATERIALS

• STACKING TINY PARTS ELECTRONICALLY

• MINING GOLD WITH ALFALFA
• ALTAIR WINS TIO2 PATENT

• NANOWIRE NANOLASERS FOR NANOSYS
• CATALYSTS CONTROL NANOTUBE DIAMETERS
  • CATALYSTS CONTROL NANOTUBE DIAMETERS (CONTINUED)
• OPTICAL PROPERTIES OF NANOTUBES

• SYNTHETASE INHIBITOR STOPS FUNGUS
• HEPATITIS C PROTEASE INHIBITOR DEVELOPED
• ANTAGONIST TO TREAT PARKINSON'S
• MICROSPHERES MAY HEAL FOOT ULCERS
• RIGHT ISOMER BETTER THAN WRONG ISOMER
  • RIGHT ISOMER BETTER THAN WRONG ISOMER (CONTINUED)
• CHINESE HERBS IN PHASE II TRIALS
• HIV DRUG WORKS AGAINST HEP B
• THREE CANDIDATES FROM OSI
  • THREE CANDIDATES FROM OSI (CONTINUED)
• PHENSERINE REDUCES ALZHEIMER'S PLAQUES
• ULTRASOUND-ACTIVATED DRUG FOR CANCER
• PEPTIDE MIMETICS LICENSED FROM PENN
• SCORPION TOXIN IS BRAIN TUMOR ANALOGUE
• ROCHE LICENSES SYNTHETIC EPO
• CLINICAL TRIAL FOR CANNABINOID COMPOUND
• ANTIBIOTIC ACQUIRED BY PANTHERIX
• PHASE III TRIALS OF HEPATITIS B DRUG
• COMBRESTATIN INHIBITS OCULAR BLOOD VESSELS
• PATENTS RELATED TO MYOSTATIN APPROVED
• ADENOSINE AGONISTS FOR SEPSIS
• NDA FILED FOR ZELAPAR
• ANTIVIRAL RNA ENTITIES PATENTED
• GRAPE JUICE IS GOOD FOR YOU
  • GRAPE JUICE IS GOOD FOR YOU (CONTINUED)
• PEPTIDE PROMOTES NERVE GROWTH
• GLUTAMATE RECEPTOR AGONISTS LICENSED
• CYCOLOSPORIN ANALOGS PASS TESTS
• RATS REGAIN FUNCTION AFTER STROKE
• SCORPION TOXIN IS ORPHAN DRUG
• ESPERION WINS HDL PATENT
• FDA PANEL SUPPORTS HEP B APPROVAL
• FEMFLURAMINE ACTIVATES MELANOCORTIN NEURONS
• IND SOUGHT FOR GLYXINS
  • IND SOUGHT FOR GLYXINS (CONTINUED)

• AYURVEDIC COMPOUND LOWERS CHOLESTEROL

• NANOSYS LICENSES UC BERKELEY IP
• MEMS, NEMS PATENT PROFILES AVAILABLE
• INTELLECTUAL PROPERTY TOUGH TO PROTECT

• MIRROR IMAGES ARE ACTIVE ANTIMICROBIALS

• COMBINING BIOLOGY WITH MASS SPEC
• MAP OF YEAST PROTEOME PUBLISHED
• NANOFAB MAKES NANOPROTEOMICS ARRAYS
• PHOSPHORYLATION SITES CATALOGED
• TRUNCATED CF PROTEIN IS FUNCTIONAL
• NMR CHARACTERIZES PROTEIN BINDING SITES
• ATHERSYS PATENTS RAGE TECHNOLOGY
• PROTEIN NETWORKS IN MUSCLE DISEASES
• Q-TRAP MASS SPECTROMETER
• PROTEOME SYSTEMS JAPAN LAUNCHED
• GRANT AWARDED FOR MEDICINE NETWORK
• FILTER SEPARATES PROTEINS AND DNA
• ZYOMYX FORMS PROTEOMIC ALLIANCE
• EMPLOYMENT OF ACTIVITY- BASED CHEMICAL PROBES
• GENETIX GROUP LANDS PROTEOMICS GRANT
• IDENTIFYING MEMBRANE AND SECRETED PROTEINS

• CHLORIDE CHANNEL STRUCTURE DETERMINED
• HITTING STRUCTURALLY CONSERVED DOMAINS
  • HITTING STRUCTURALLY CONSERVED DOMAINS (CONTINUED)
  • Hitting Structurally Conserved Domains (Continued)

• VIRTUAL SCREENING OF TOXIN INHIBITORS
• "MONOPHORE" SCREENING TECHNIQUE PATENTED
• DESIGN YOUR OWN MICROFLUIDICS CHIP
• NANOLITHOGRAPHY BUILDS DNA ARRAYS
• NANOTECH BIOTERROR SENSORS DEVELOPED
• SCREENING FOR ANTIFUNGALS
  • SCREENING FOR ANTIFUNGALS (CONTINUED)

• IBM BUILDS MOLECULAR SCALE TRANSISTOR

• COBRA SEES THIN FILMS AT ATOMIC RESOLUTION

LIST OF TABLES

Table 1 U.S. MARKET FOR BIOSNESORS AND BIOELECTRONICS, THROUGH 2006 ($ MILLIONS)

Table 2 U.S. USER EXPENDITURES FOE MEDICAL IMAGING EQUIPMENT AND RELATED PRODUCTS, THROUGH 2007 ($ MILLIONS)

Table 3 WORLDWIDE MARKET FOR INHIBITORS AND BLOCKERS, THROUGH 2007 ($ MILLIONS)

Table 4 VALUE OF THE AGING BABY BOOMER PHARMACEUTICAL & COSMETIC SALES ¾ U.S., THROUGH 2006 ($ MILLIONS AT MANUFACTURERS' LEVEL)

Table 5 MARKET FOR REPRODUCTIVE TECHNOLOGY PRODUCTS AND PROCEDURES, THROUGH 2006 ($ MILLIONS)

Table 6 WORLDWIDE DIABETES MARKET, THROUGH 2007 ($ MILLIONS)

Table 7 U.S. MDK APPLICATIONS MARKET AT U.S. MANUFACTURERS' SALES LEVELS, THROUGH 2006 ($ MILLIONS)

Table 8 GLOBAL MARKET FOR PHARMACEUTICAL (DRUG) INERT INGREDIENTS, THROUGH 2006 (MILLIONS OF KG)

Table 9 THE U.S. GENERIC DRUG MARKET, THROUGH 2006 ($ BILLIONS)

Table 10 TRENDS IN DRUG SALES, THROUGH 2007 ($ BILLIONS)  

LIST OF FIGURES

Figure 1 U.S. MARKET FOR BIOSNESORS AND BIOELECTRONICS, 2001 AND 2006 ($ MILLIONS)

Figure 2 U.S. USER EXPENDITURES FOE MEDICAL IMAGING EQUIPMENT AND RELATED PRODUCTS, 2000-2007 ($ MILLIONS)

Figure 3 WORLDWIDE MARKET FOR INHIBITORS AND BLOCKERS, 2002 AND 2007 ($ MILLIONS)

Figure 4 VALUE OF THE AGING BABY BOOMER PHARMACEUTICAL & COSMETIC SALES ¾ U.S., 2001 AND 2006 ($ MILLIONS AT MANUFACTURERS' LEVEL)

Figure 5 MARKET FOR REPRODUCTIVE TECHNOLOGY PRODUCTS AND PROCEDURES, 2001 AND 2006 ($ MILLIONS)

Figure 6 WORLDWIDE DIABETES MARKET, 2000-2007 ($ MILLIONS)

Figure 7 U.S. MDK APPLICATIONS MARKET AT U.S. MANUFACTURERS' SALES LEVELS, 2001 AND 2006 ($ MILLIONS)

Figure 8 PERCENTAGE OF THE U.S. GENERIC DRUG MARKET HELD BY LEADING THERAPEUTIC CATEGORIES, 2001